These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22283751)

  • 41. Treating schizophrenia: novel targets for the cholinergic system.
    Money TT; Scarr E; Udawela M; Gibbons AS; Jeon WJ; Seo MS; Dean B
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):241-56. PubMed ID: 20053170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting muscarinic receptors to treat schizophrenia.
    Foster DJ; Bryant ZK; Conn PJ
    Behav Brain Res; 2021 May; 405():113201. PubMed ID: 33647377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
    Davie BJ; Christopoulos A; Scammells PJ
    ACS Chem Neurosci; 2013 Jul; 4(7):1026-48. PubMed ID: 23659787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allosteric modulators and selective agonists of muscarinic receptors.
    Holzgrabe U; De Amici M; Mohr K
    J Mol Neurosci; 2006; 30(1-2):165-8. PubMed ID: 17192667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.
    Tobin AB
    Nat Rev Drug Discov; 2024 Oct; 23(10):743-758. PubMed ID: 39143241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Classics in Chemical Neuroscience: Xanomeline.
    Bender AM; Jones CK; Lindsley CW
    ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates.
    Andersen MB; Croy CH; Dencker D; Werge T; Bymaster FP; Felder CC; Fink-Jensen A
    PLoS One; 2015; 10(4):e0122722. PubMed ID: 25880220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bitopic Binding Mode of an M
    Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
    Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting glutamate synapses in schizophrenia.
    Field JR; Walker AG; Conn PJ
    Trends Mol Med; 2011 Dec; 17(12):689-98. PubMed ID: 21955406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of muscarinic receptor agonists on animal models of psychosis.
    Karan RS; Ravishankar P; Pandhi P
    Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):169-72. PubMed ID: 10893700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Muscarinic receptors in schizophrenia.
    Dean B; Bymaster FP; Scarr E
    Curr Mol Med; 2003 Aug; 3(5):419-26. PubMed ID: 12942995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
    Meltzer HY; Massey BW; Horiguchi M
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
    Buchanan RW; Freedman R; Javitt DC; Abi-Dargham A; Lieberman JA
    Schizophr Bull; 2007 Sep; 33(5):1120-30. PubMed ID: 17641146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outline of therapeutic interventions with muscarinic receptor-mediated transmission.
    Jakubík J; Šantrůčková E; Randáková A; Janíčková H; Zimčík P; Rudajev V; Michal P; El-Fakahany EE; Doležal V
    Physiol Res; 2014; 63(Suppl 1):S177-89. PubMed ID: 24564657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
    Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
    Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
    Scarr E; Dean B
    J Neurochem; 2008 Dec; 107(5):1188-95. PubMed ID: 18957051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.